Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;63(4):587-93.
doi: 10.1016/j.jaad.2009.11.011. Epub 2010 Aug 7.

A pilot study of emollient therapy for the primary prevention of atopic dermatitis

Eric L Simpson  1 , Trista M Berry, Peter A Brown, Jon M Hanifin
Affiliations

A pilot study of emollient therapy for the primary prevention of atopic dermatitis

Eric L Simpson et al. J Am Acad Dermatol. 2010 Oct.

Abstract

Background: Prevention strategies in atopic dermatitis (AD) using allergen avoidance have not been consistently effective. New research reveals the importance of the skin barrier in the development of AD and possibly food allergy and asthma. Correcting skin barrier defects from birth may prevent AD onset or moderate disease severity.

Objective: We sought to determine the feasibility of skin barrier protection as a novel AD prevention strategy.

Methods: We enrolled 22 neonates at high risk for developing AD in a feasibility pilot study using emollient therapy from birth.

Results: No intervention-related adverse events occurred in our cohort followed up for a mean time of 547 days. Of the 20 subjects who remained in the study, 3 (15.0%) developed AD, suggesting a protective effect when compared with historical controls. Skin barrier measurements remained within ranges seen in normal-appearing skin.

Limitations: No conclusions regarding efficacy can be made without a control group.

Conclusions: Skin barrier repair from birth represents a novel and feasible approach to AD prevention. Further studies are warranted to determine the efficacy of this approach.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Subject enrollment and follow-up diagram.
Figure 2
Figure 2
Individual subject data with length of follow-up and outcomes. AD, Atopic dermatitis.
Figure 3
Figure 3
Transepidermal water loss (TEWL) and capacitance measurements during study from back of arm. Asterisks and dots indicate outliers.
See this image and copyright information in PMC

References

    1. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1–191. - PMC - PubMed
    1. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol. 2008 Jan;121(1):116–121. - PubMed
    1. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics. 2008 Apr;121(4):e850–856. Epub 2008 Mar 10. - PubMed
    1. Abrahamsson TR, Jakobsson T, Bottcher MF, Fredrikson M, Jenmalm MC, Bjorksten B, Oldaeus G. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007 May;119(5):1174–1180. - PubMed
    1. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol. 2007 Jan;119(1):184–191. - PubMed

Publication types

MeSH terms

Substances